Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Ephrin receptor A2 (EphA2) exhibits context-dependent roles in cancer, acting as a tumor promoter or suppressor.
• The mechanisms regulating EphA2's tumor-suppressive functions are not fully understood.

Purpose of the Study:

• To investigate the role of RNF5 in regulating EphA2 stability and function.
• To elucidate the impact of RNF5-EphA2 interaction on HER2-negative breast cancer progression and patient outcomes.

Main Methods:

• Co-immunoprecipitation to assess RNF5-EphA2 interaction.
• Western blotting to analyze protein levels and phosphorylation.
• Cell adhesion and migration assays.
• Xenograft tumor growth studies in mice.
• Correlation analysis of RNF5 and EphA2 expression with patient survival data.

Main Results:

• RNF5 directly interacts with EphA2, promoting its ubiquitination and degradation, thereby reducing EphA2 stability and cell surface presence.
• RNF5 inhibition leads to increased EphA2 levels, decreased ERK phosphorylation, and elevated p53 expression in HER2-negative breast cancer cells.
• Silencing RNF5 enhances cell adhesion, reduces cell migration, and suppresses tumor growth in vivo.
• RNF5 expression is inversely correlated with EphA2 expression in breast cancers.
• High EphA2 and low RNF5 levels correlate with better survival in ER-positive, HER2-negative breast cancer patients.

Conclusions:

• RNF5 negatively regulates EphA2 by targeting it for degradation, thus inhibiting its tumor-suppressive functions in HER2-negative breast cancer.
• Targeting RNF5 may represent a therapeutic strategy to restore EphA2's tumor-suppressive activity and improve outcomes for specific breast cancer subtypes.